Rani Therapeutics

63 articles about Rani Therapeutics

• Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

  3/15/2024

  Rani Therapeutics Holdings, Inc. today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2023 and provide a business update on Wednesday, March 20 after the close of trading.

• Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111)

  2/5/2024

  Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced positive topline results from its Phase 1 clinical study of RT-111, a RaniPill® capsule containing an ustekinumab biosimilar, CT-P43. In the study, RT-111 was well-tolerated and delivered ustekinumab with high bioavailability.

• Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update

  11/8/2023

  Rani Therapeutics Holdings, Inc. reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.

• The RaniPill® Capsule, Rani Therapeutics’ Oral Delivery Platform, was Well-Tolerated in 60-Day, Repeat-Administration, GLP Safety Study

  10/25/2023

  Rani Therapeutics Holdings, Inc., a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, announced preclinical data supporting the safety and tolerability of the RaniPill® drug delivery platform following 60-day repeat administration.

• Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study

  10/19/2023

  Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the successful oral delivery of a monoclonal antibody, Humira® (adalimumab), via its high-capacity capsule, the RaniPill® HC, in a preclinical study.

• Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)

  9/18/2023

  Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the initiation of a Phase 1 clinical trial to evaluate the safety and tolerability of RT-111, an orally administered RaniPill®GO capsule containing an ustekinumab biosimilar, CT-P43.

• Rani Therapeutics to Participate in August 2023 Investor Conferences

  8/4/2023

  Rani Therapeutics Holdings, Inc., a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, announced that the Company will participate in three upcoming investor conferences in August 2023.

• Rani Therapeutics’ Presentation On Oral Delivery of PTH for Osteoporosis Named Presidential Poster Competition Winner at ENDO 2023 Annual Conference

  6/21/2023

  Rani Therapeutics Holdings, Inc. announced that its abstract entitled “An Orally Administered Robotic Pill (RP) Reliably and Safely Delivers the Human Parathyroid Hormone Analog hPTH (1-34) (Teriparatide) With High Bioavailability in Healthy Human Volunteers: A Phase 1 Study,” presented on June 17.

• Rani Therapeutics Announces Acceptance of Late-Breaking Abstract of Oral Delivery of GLP-1 Agonist at the American Diabetes Association Annual Conference

  6/8/2023

  Rani Therapeutics Holdings, Inc. today announced that a late-breaking abstract “Oral Delivery of a GLP-1 Agonist with High Bioavailability in Dogs and Humans” has been selected for poster presentation at the American Diabetes Association’s (ADA) Scientific Sessions taking place on June 23 - 26, 2023.

• Rani Therapeutics and Celltrion Expand Partnership to Include Adalimumab Biosimilar for RT-105This is the second deal announced between Rani and Celltrion, building upon a previously announced partnership for ustekinumab biosimilar for RT-111

  6/5/2023

  Rani Therapeutics Holdings, Inc. announced that it has expanded its partnership with Celltrion by entering into an agreement for the development of RT-105, an orally administered adalimumab biosimilar.

• Rani Therapeutics to Present at the 2023 Jefferies Healthcare Conference

  6/1/2023

  Rani Therapeutics Holdings, Inc. announced the company’s Chief Executive Officer, Talat Imran, and Chief Financial Officer, Svai Sanford, will present at the Jefferies Healthcare Conference on Thursday, June 8, 2023 from 4:00-4:25 pm E.T. in Track 3.

• Rani Therapeutics Announces Acceptance of Three Abstracts for Presentation at ENDO 2023 Annual Conference

  5/31/2023

  Rani Therapeutics Holdings, Inc. today announced that three submitted abstracts were accepted for poster presentations at the 105th annual meeting of The Endocrine Society (ENDO 2023) taking place June 15-18, 2023, in Chicago, Illinois.

• Rani Therapeutics Appoints Kate McKinley as Chief Business Officer

  5/24/2023

  Rani Therapeutics Holdings, Inc. today announced that it has appointed Kate McKinley as its Chief Business Officer.

• Rani Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Corporate Update

  3/22/2023

  Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial results for the quarter and full year ended December 31, 2022 and provided a corporate update.

• Rani Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates

  3/16/2023

  Rani Therapeutics Holdings, Inc. announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2022 on Wednesday, March 22 after the close of trading.

• Celltrion and Rani Therapeutics Partner on Development of Oral Monoclonal Antibody Treatment

  1/9/2023

  Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has partnered with Celltrion for the development of RT-111, an orally administered ustekinumab biosimilar.

• Rani Therapeutics Receives Feedback from Pre-IND Meeting with FDA; Provides Pipeline Update

  1/5/2023

  Rani Therapeutics Holdings, Inc. announced that it completed a pre-Investigational New Drug meeting with the U.S. Food and Drug Administration with respect to RT-102, the RaniPill™ GO containing a proprietary formulation of human parathyroid hormone analog for the potential treatment of osteoporosis, and provided a corporate update.

• Rani Therapeutics Announces Repeat-Dose Topline Results from RT-102 Phase 1 Study

  12/6/2022

  Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced topline results from Part 2 (repeat-dose portion) of the Phase 1 study of RT-102, the RaniPill™ GO capsule containing a proprietary formulation of human parathyroid hormone (1-34) analog (PTH) being developed for the treatment of osteoporosis.

• Rani Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

  11/10/2022

  Rani Therapeutics Holdings, Inc., a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, reported financial results for the quarter ended September 30, 2022, and provided a corporate update.

• Rani Therapeutics to Present at the 2022 Stifel Healthcare Conference

  11/9/2022

  Rani Therapeutics Holdings, Inc., a clinical stage biotherapeutics company focused on the oral delivery of biologics and drugs, announced that the company will present at the Stifel Healthcare Conference taking place on November 15 - 16, 2022.